Stay updated on Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial

Sign up to get notified when there's something new on the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    1%
    Check dated 2025-07-04T03:58:57.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.8%
    Check dated 2025-06-19T19:54:31.000Z thumbnail image
  4. Check
    29 days ago
    No Change Detected
  5. Check
    36 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:22:54.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T06:09:45.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    The webpage has updated its date references, removing older dates and adding new ones for May 2025 and September 2027.
    Difference
    0.7%
    Check dated 2025-05-14T23:35:33.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    The web page has been updated to reflect the latest results and details of a study investigating Sacituzumab Govitecan for metastatic castration-resistant prostate cancer, including new reporting dates and specific eligibility criteria for participants.
    Difference
    7%
    Check dated 2025-04-30T14:24:58.000Z thumbnail image

Stay in the know with updates to Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page.